Literature DB >> 7978109

Mitochondrial function reflected by the decarboxylation of [13C]ketoisocaproate is impaired in alcoholics.

A Witschi1, S Mossi, B Meyer, E Junker, B H Lauterburg.   

Abstract

Mitochondria of patients with alcoholic liver disease exhibit structural abnormalities, and mitochondria isolated from animals exposed to ethanol are functionally deficient when studied in vitro. To assess possible functional consequences of these ethanol-associated alterations in vivo, we measured mitochondrial function in alcoholics noninvasively with a breath test. A mitochondrial function, the decarboxylation of ketoisocaproate (KICA), was assessed by measuring the exhalation of 13CO2 following the administration of 1 mg/kg 2-keto[1-13C]isocaproic acid, the decarboxylation of which occurs in mitochondria. The results of the KICA breath test in 12 alcoholic subjects were compared with the results in healthy controls and patients with nonalcoholic liver disease. The peak exhalation of 13CO2 and the fraction of the administered dose decarboxylated in 120 min were both significantly lower in alcoholics than in healthy controls and patients with nonalcoholic liver disease. In alcoholics, KICA decarboxylation was impaired in the presence of normal quantitative liver function tests such as the aminopyrine breath test and galactose elimination capacity, indicating that KICA decarboxylation does not simply reflect a decreased functional hepatic mass. The enrichment of circulating KICA with [13C]KICA was similar in alcoholics and controls, indicating that a decreased bioavailability or an increased dilution of labeled KICA cannot account for the decreased exhalation of 13CO2. It is concluded that mitochondrial function as reflected by KICA decarboxylation is impaired in chronic alcoholics. The functional impairment is specific for ethanol abuse and not a reflection of decreased global hepatic function. KICA decarboxylation could thus be useful as a marker for excessive ethanol consumption.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7978109     DOI: 10.1111/j.1530-0277.1994.tb00065.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  7 in total

1.  13C-alpha-Ketoisocaproic acid breath test revisited: an in-depth reproducibility study advocates an extended breath sampling period.

Authors:  Anna Kasicka-Jonderko; Krzysztof Jonderko; Magdalena Kamińska; Monika Bielecka; Barbara Błońska-Fajfrowska
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

Review 2.  Laboratory approach to mitochondrial diseases.

Authors:  D Parra; A González; C Mugueta; A Martínez; I Monreal
Journal:  J Physiol Biochem       Date:  2001-09       Impact factor: 4.158

3.  Role of Mitochondria in Alcoholic Liver Disease.

Authors:  Carmen García-Ruiz; Neil Kaplowitz; José C Fernandez-Checa
Journal:  Curr Pathobiol Rep       Date:  2013-09-01

Review 4.  Clinical utility of 13C-liver-function breath tests for assessment of hepatic function.

Authors:  P Afolabi; M Wright; S A Wootton; A A Jackson
Journal:  Dig Dis Sci       Date:  2012-08-17       Impact factor: 3.199

5.  Exploring Liver Mitochondrial Function by 13C-Stable Isotope Breath Tests: Implications in Clinical Biochemistry.

Authors:  Emilio Molina-Molina; Harshitha Shanmugam; Domenica Di Palo; Ignazio Grattagliano; Piero Portincasa
Journal:  Methods Mol Biol       Date:  2021

Review 6.  Dynamic carbon 13 breath tests for the study of liver function and gastric emptying.

Authors:  Leonilde Bonfrate; Ignazio Grattagliano; Giuseppe Palasciano; Piero Portincasa
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-10-21

Review 7.  Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests.

Authors:  Agostino Di Ciaula; Giuseppe Calamita; Harshitha Shanmugam; Mohamad Khalil; Leonilde Bonfrate; David Q-H Wang; Gyorgy Baffy; Piero Portincasa
Journal:  Int J Mol Sci       Date:  2021-07-19       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.